

CanREValue

Value-based decisions from Real World Evidence

Newsletter

Issue 8 | Summer 2020

Study Objectives:

Objective 1: (ongoing)

- ❖ Develop comprehensive understanding of the current state of RWE nationally & internationally
- ❖ Keep current on emerging/new information related to RWE in Canada and beyond

Objective 2: (established & ongoing)

- ❖ Establish formal national working groups dedicated to policy and methodological application of RWE, and collaboratively & iteratively develop a working framework

Objective 3: (ongoing)

- ❖ Validate the developed framework through the completion of a multi-province RWE project

Objective 4: (ongoing)

- ❖ Employ knowledge translation strategies to establish and integrate the final RWE framework

CANREVALUE 2020 GOES VIRTUAL

Due to the COVID-19 pandemic, we had to cancel our annual CanREValue in-person meeting. We are pleased to announce that we have adapted the in-person meeting to a virtual format. The virtual CanREValue meeting will be held on August 13th for members of the CanREValue Collaboration. We will partner with ARCC to host a webinar later in 2020 to provide a public update on work to date, including a Virtual Meeting update.

Please email us at CanREValue@cc-arcc.ca if you have any questions or need additional information.

CANREVALUE STAKEHOLDER CONSULTATIONS

We are pleased that the public consultation on the progress of the Working Groups has been completed. Since November 16th, 2019, we have completed one Engagement Webinar ([slide, presentation](#)), and public consultation on three Working Group Reports ([link](#)). We have received much feedback from diverse stakeholders that has been very informative to the development of the framework. On April 21st, we released the Data Working Groups' responses to the feedback from the consultation ([link](#)).

Next Steps: Over the next few months, we will review the feedback provided for the Interim Policy Working Group Report and the Interim Method Working Group Report. Please email us at CanREValue@cc-arcc.ca if you have any questions or need additional information.



WORKING GROUP UPDATES AND NEXT STEPS:

Working Group	Updates & Next Steps
RWE Planning and Drug Selection	Updates: <ul style="list-style-type: none"> Review and responded to feedback from stakeholder consultation Next Steps: <ul style="list-style-type: none"> Prepare for Virtual Meeting discussions
RWE Data	Updates: <ul style="list-style-type: none"> Held interprovincial analysis meeting for cohort creation and algorithm development Continued contract discussions for data sharing Reviewed and responded to the feedback from stakeholder consultation Next Steps: <ul style="list-style-type: none"> Continue with real-world analysis (cohort creation, survival analysis) in 9 provinces
RWE Methods	Updates: <ul style="list-style-type: none"> Completed stakeholder consultation on the Interim Method Report Next Steps: <ul style="list-style-type: none"> Review and respond to the feedback from consultation
RWE Reassessment and Uptake	Updates: <ul style="list-style-type: none"> Review and responded to feedback from stakeholder consultation Next Steps: <ul style="list-style-type: none"> Prepare for Virtual Meeting discussions
Stakeholder Engagement	Updates: <ul style="list-style-type: none"> Completed the open stakeholders consultation on three Working Group Reports Released response to the Interim Data Working Group Report (here) Next Steps: <ul style="list-style-type: none"> Release response to the Interim Policy Working Group Report and Interim Method Working Group Report

CANREVALUE CORE RESEARCH TEAM UPDATE – CONGRATULATIONS DR. TADROUS!



We are pleased to announce that Dr. Mina Tadrous has been promoted to Co-Principal Investigator on the CanREValue CIHR-PHSI research grant (Effective May 1, 2020). Since joining the CanREValue core research team, Mina has taken on increasing responsibilities across the CanREValue Collaboration including co-leading the Engagement WG with Bill Evans, and spearheading three successful public consultations for the Policy, Data, and Method WGs. We welcome Mina to this new leadership role and look forward to continuing to work with him to further the work of the CanREValue Collaboration.



MEMBER SPOTLIGHT – MICHAEL RAPHEL

Q: What is your research focused on, and what are your long-term career goals?

My research focus is in population-based cancer care. My main goals are to: (1) Identify ways to optimize the coordination and delivery of cancer care services; (2) Identify gaps in care, disparities in access to treatment, and uptake of cancer therapies; (3) Ensure that we truly understand the real-world effectiveness and toxicity of cancer medicines to help patients, families, clinicians and payers make informed decisions about use of cancer medicines.



Q: What aspect of the CanREValue project are you the most excited to work on?

I think the entire CanREValue collaboration is a timely and fascinating project. I am very excited about the opportunity to foster pan-Canadian collaborations and to learn from the amazing group of talented scientists/researchers across the country. I'm really keen to see what types of data sources our colleagues from other provinces have access to, and to share what we have here in Ontario. I'm also really excited to learn from the brilliant methodologists and statisticians involved with the collaboration.

Q: What has been the most interesting aspect of this project for you so far?

The in-person Mock Drug Reassessment was a really fun experience. I'm looking forward to having COVID-19 behind us, so that we can all meet in person once again.

Q: How can we reach you?

Email is best: michaelj.raphael@sunnybrook.ca

Recent Publications/Presentations:

Real-world evidence study published by the CanREValue team:

[Real-world comparative effectiveness of second-line ipilimumab for metastatic melanoma: a population-based cohort study in Ontario, Canada](#), Dai, W.F., Beca, J.M., Croxford, R. et al. BMC Cancer 20, 304 (2020).

Commentary on RWE by members of the CanREValue Working Group:

[Developing a Canadian Real-World Evidence Action Plan across the Drug Life Cycle](#), Tadrous, M., Ahuja, T., Ghosh, B., Kropp, R., Healthcare Policy 15(4), May 2020 41-47.doi:10.12927/hcpol.2020.26225

Coming Soon!

CanREValue 2020 Virtual Meeting

